Under Development

Biofilm Susceptibility testing

The National Institutes of Health reports that 80% of all infectious diseases are caused by organisms in a biofilm state and biofilms are the predominant cause of chronic pulmonary infections in Cystic Fibrosis, Ventilator Associated Pneumonia and burn or wound infections. Biofilm infections are up to 1000 times more difficult to treat than conventional infections. bioFILM PATM is the first in-vitro diagnostic tool designed to help physicians fight resistant biofilm diseases..

As easy to use as an MIC test, it’s the only test of its kind that provides Pseudomonas susceptibilities at serum breakpoint levels . Choosing the right antibiotics to treat infections requires an in-vitro susceptibility test that that closely approximates the in-vivo condition, and bioFILM PATM is the world’s first susceptibility test for organism in planktonic and biofilm states, testing the bacteria against single and combination antibiotics. bioFILM PATM provides improved susceptibility information not only for Cystic Fibrosis lung infections but also for pneumonia, burns, wounds and other chronic Pseudomonas infections.

The bioFILM PATM kit is approved by Health Canada for medical diagnostic use and licensed for sale in Canada and Israel.

Innovotech can provide in-house bioFILM PATM and other biofilm bacterial susceptibility testing services for interested parties both within Canada and globally.

All in-house biofilm bacterial susceptibility testing and associated Information are to be used for research or informational purposes only and are not intended to be used for any medical, diagnostic, regulatory or any other purposes whatsoever. The biofilm susceptibility tests and associated Information are not approved by the U.S. Food and Drug Administration.